Irving-based molecular science and technology company Caris Life Sciences has secured $400 million in capital funding from OrbiMed and Braidwell, bringing Caris’ total funding to $1.7 billion since 2018. Founded in 2008, Caris is building a database of more than 450,000 tumor profiles and is working on a treatment to detect numerous cancer types through a simple blood test as well as personalized treatment methods based on a patient’s molecular profile.
Presented by D CEO Healthcare Brief.